Pfizer suspends tanezumab trial per FDA's request
NEW YORK Reports of worsening conditions among patients has led drug maker Pfizer to suspend a clinical trial of a treatment for osteoarthritis, Pfizer said Wednesday.
The world’s largest drug company suspended a trial of the investigational drug tanezumab at the request of the Food and Drug Administration following reports that patients taking the drug experienced a worsening of symptoms, leading to joint replacement, which had not been found in test subjects who did not have osteoarthritis.
Pfizer will suspend recruitment of new patients and dosing of existing patients. The FDA has also asked Pfizer to assess what the findings could mean for patients in clinical trials of tanezumab for other conditions, such as cancer pain, interstitial cystitis, chronic lower back pain and diabetic peripheral neuropathy.